IP
IPSC.US Century Therapeutics Inc
- Market cap
- USD 300M
- P/E
- -
- P/B
- 1.43x
- ROE
- -50.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IPSC.US undervalued?
Graham numberThe Graham number of Century Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Century Therapeutics Inc fundamental analysis
No fundamental analysis for Century Therapeutics Inc yet.
Century Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered wi…
Full company profileCentury Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Century Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 951M | 470M | 0.00 | 0.00 | 1.06M | 5.20M | 2.24M | 6.59M | 109M | 0.00 |
| Gross Profit | 62.0M | 2.48M | -249K | -1.75M | -4.58M | 5.20M | 2.24M | 6.59M | 96.1M | - |
| Operating Income | - | - | -20.0M | -49.2M | -94.9M | -134M | -147M | -138M | -15.0M | -116M |
| EBITDA | - | - | -245M | -51.8M | -90.8M | -121M | -121M | -111M | 3.45M | -95.8M |
| Net Income | - | - | -245M | -53.6M | -95.8M | -131M | -137M | -127M | -9.58M | -106M |
| EPS | - | - | -4.46 | -0.98 | -1.74 | -2.27 | -2.30 | -1.61 | -0.11 | -0.51 |
| Balance Sheet | ||||||||||
| Total Assets | 845M | 758M | 90.9M | 107M | 437M | 487M | 361M | 353M | 224M | 263M |
| Total Liabilities | 485M | 576M | 183M | 213M | 41.1M | 184M | 176M | 192M | 64.8M | 52.7M |
| Shareholders' Equity | 360M | 182M | -91.9M | -106M | 396M | 303M | 185M | 161M | 159M | 210M |
| Cash & Short-term Investments | 208K | 21.5M | 81.5M | 75.8M | 223M | 315M | 173M | 189M | 117M | 117M |
| Total Debt | - | - | - | 21.6M | 25.1M | 49.4M | 48.2M | 53.8M | 43.6M | 37.5M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 104M | - | -16.2M | -41.3M | -89.0M | 14.1M | -88.3M | -110M | -104M | -89.7M |
| Capital Expenditure | 29.4M | 11.1M | 2.46M | 9.83M | 45.0M | 30.6M | 13.7M | 154K | 848K | 2.42M |
| Free Cash Flow | - | - | -18.6M | -51.1M | -134M | -16.6M | -102M | -110M | -105M | -92.2M |
| Ratios | ||||||||||
| ROE | - | - | - | - | -24.2% | -43.2% | -74.0% | -78.4% | -6.0% | -50.6% |
| ROA | - | - | -269.3% | -50.2% | -21.9% | -26.9% | -37.9% | -35.8% | -4.3% | -40.4% |
| Net Profit Margin | - | - | - | - | -9,057.1% | -2,518.4% | -6,115.1% | -1,920.9% | -8.8% | - |
| Debt to Equity | - | - | - | - | 0.06x | 0.16x | 0.26x | 0.33x | 0.27x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Century Therapeutics Inc dividends
Century Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Century Therapeutics Inc
- Insiders 8.58%
- Institutions 88.02%
- Public & others 3.40%
- Shares outstanding 182M
- Free float 102M
Top funds holding IPSC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.34M | 2.39% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.95M | 1.63% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.34M | 0.74% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.18M | 0.65% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 719K | 0.40% | +1.40% | Sep 2026 |
| Northern Small Cap Value | 550K | 0.30% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 459K | 0.25% | -12.93% | Sep 2026 |
| iShares Micro-Cap ETF | 370K | 0.20% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 299K | 0.17% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 230K | 0.13% | 0.00% | Sep 2026 |
| Invesco Russell 2000® Dynamic Mltfct ETF | 221K | 0.12% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 219K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 200K | 0.11% | -0.05% | Sep 2026 |
| Vanguard Health Care ETF | 192K | 0.11% | +0.11% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 190K | 0.10% | +0.27% | Oct 2026 |
| Bridge Builder Small Cap Fund | 183K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Small Cap Value Index | 182K | 0.10% | +3.66% | Aug 2026 |
| Fidelity Series Total Market Index | 168K | 0.09% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 164K | 0.09% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 134K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding IPSC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 17.8M | 9.80% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 17.8M | 9.80% | 0.00% | Jun 2026 |
| Versant Venture Management LLC | 12.2M | 6.71% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 9.46M | 5.22% | -0.26% | Jun 2026 |
| VR Adviser, LLC | 8.70M | 4.80% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 8.70M | 4.80% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 8.70M | 4.80% | 0.00% | Jun 2026 |
| BlackRock Inc | 8.09M | 4.46% | +430.81% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.70M | 3.15% | +0.31% | Jun 2026 |
| Balyasny Asset Management LLC | 5.52M | 3.05% | +10.07% | Jun 2026 |
| Point72 Asset Management, L.P. | 4.98M | 2.75% | -16.50% | Jun 2026 |
| Seven Fleet Capital Management LP | 4.35M | 2.40% | +47.49% | Jun 2026 |
| Woodline Partners LP | 4.26M | 2.35% | +39.89% | Jun 2026 |
| Millennium Management LLC | 4.19M | 2.31% | -10.12% | Jun 2026 |
| Trails Edge Capital Partners, LP | 4.13M | 2.28% | +68.77% | Jun 2026 |
| Spruce Street Capital LP | 4.06M | 2.24% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 3.79M | 2.09% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.98M | 1.64% | +128.90% | Jun 2026 |
| Two Sigma Investments LLC | 2.70M | 1.49% | +13.81% | Jun 2026 |
| Dafna Capital Management LLC | 2.40M | 1.32% | -1.39% | Jun 2026 |
Century Therapeutics Inc company profile
- Company name
- Century Therapeutics Inc
- Ticker
- IPSC.US
- Exchange
- USA Stocks
- Listed since
- Jun 18, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 78
- Fiscal year end
- December
- Address
- 25 North 38th Street, Philadelphia, PA, United States, 19104
- Phone
- 267 817 5790
- Website
- centurytx.com
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Century Therapeutics Inc management
8- Dr. Brent Pfeiffenberger M.B.A., Pharm.D.President, CEO & Chairman · born 1978
- Dr. Gregory Russotti Ph.D.Chief Technology & Manufacturing Officer · born 1967
- Dr. Chad A. Cowan Ph.D.Chief Scientific Officer · born 1972
- Mr. Douglas Carr CPASenior VP of Finance & Operations, Principal Financial Officer and Secretary
- Krista Kauppinen J.D., Ph.D.VP, General Counsel & Head of Intellectual Property
- Ms. Megan BilsonChief People Officer
- Michael Naso Ph.D.Senior VP of Cell Engineering
- Ms. Elizabeth DevlinVP & Head of Development